GenomeDx and Color to offer hereditary cancer risk genetic testing for prostate cancer San Diego and Burlingame, CA – May 12, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a collaboration with Color to offer its Color Test, a hereditary cancer risk genetic test that analyzes 30 genes. […]
Category: Press Releases
GenomeDx and Mayo Clinic Enter Agreement to Conduct Validation Study of Decipher® Prostate Cancer Test in Patients Receiving Biopsy Prior to Treatment
Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO – November 11, 2014 – GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® […]
Decipher® Predicts Metastasis and Identifies Biomarkers Predictive of Aggressive Disease in African American Men
Study published by the Journal of Clinical Oncology provides biomarker insights into racial disparity in prostate cancer outcomes & shows that Decipher successfully stratifies African American men for metastasis San Diego, August 4, 2015 – GenomeDx Biosciences announced today that its commercially-available Decipher® testing platform identified, with statistical significance, a set of prostate cancer biomarkers […]